{"id":"ray1216","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5422898","moleculeType":null,"molecularWeight":"639.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RAY1216 is being developed by Guangdong Raynovent Biotech Co., Ltd as a phase 3 candidate. Limited public information is available regarding its precise mechanism of action, molecular target, or therapeutic indication at this stage of development.","oneSentence":"RAY1216 is an investigational therapeutic targeting a specific molecular pathway relevant to its indication, currently in phase 3 clinical development.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:16.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06169085","phase":"PHASE1","title":"Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-08-24","conditions":"Elder","enrollment":32},{"nctId":"NCT06362460","phase":"PHASE1","title":"Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-09-18","conditions":"Pharmacokinetics","enrollment":6},{"nctId":"NCT06031454","phase":"PHASE1","title":"Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-09-01","conditions":"Drug Drug Interaction","enrollment":56},{"nctId":"NCT06160622","phase":"PHASE1","title":"Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-09-26","conditions":"Kidney Impairment","enrollment":16},{"nctId":"NCT06161259","phase":"PHASE1","title":"Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-09-14","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT05620160","phase":"PHASE3","title":"Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2022-11-12","conditions":"Mild to Moderate COVID-19","enrollment":1359},{"nctId":"NCT05829551","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2022-05-20","conditions":"COVID-19 (Coronavirus Disease 2019)","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RAY1216","genericName":"RAY1216","companyName":"Guangdong Raynovent Biotech Co., Ltd","companyId":"guangdong-raynovent-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}